FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
Petr NovakReinhold SchmidtEva KontsekovaBranislav KovacechTomas SmolekStanislav KatinaLubica FialovaMichal PrcinaVojtech ParrakPeter Dal-BiancoMartin BrunnerWolfgang StaffenMichael RainerMatej OndrusStefan RopeleMiroslav SmisekRoman SivakNorbert ZilkaBengt WinbladMichal NovakPublished in: Alzheimer's research & therapy (2018)
The studies are registered with the EU Clinical Trials Register and ClinicalTrials.gov : the preceding first-in-human study under EudraCT 2012-003916-29 and NCT01850238 (registered on 9 May 2013) and the follow-up study under EudraCT 2013-004499-36 and NCT02031198 (registered 9 Jan 2014), respectively.